Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3
The development and spread of <i>Mycobacterium tuberculosis</i> multi-drug resistant strains still represent a great global health threat, leading to an urgent need for novel anti-tuberculosis drugs. Indeed, in the last years, several efforts have been made in this direction, through a n...
Main Authors: | Giulia Degiacomi, Juan Manuel Belardinelli, Maria Rosalia Pasca, Edda De Rossi, Giovanna Riccardi, Laurent Roberto Chiarelli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/10/2/623 |
Similar Items
-
Multiple Mutations in <named-content content-type="genus-species">Mycobacterium tuberculosis</named-content> MmpL3 Increase Resistance to MmpL3 Inhibitors
by: Matthew B. McNeil, et al.
Published: (2020-10-01) -
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the <i>Mycobacterium tuberculosis</i> DprE1 Enzyme
by: José Manuel Ezquerra-Aznárez, et al.
Published: (2022-01-01) -
The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection
by: John T. Williams, et al.
Published: (2024-01-01) -
MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections
by: Wei Li, et al.
Published: (2018-07-01) -
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug
by: Giorgia Mori, et al.
Published: (2020-02-01)